The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENTO | +61.11% | -100% | -88.11% | -45% |
| S&P | +13.22% | +85.17% | +13.11% | +0% |
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
No news articles found for GridAI Technologies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $7.94M | 386.3% |
| Market Cap / Employee | $3.97M | 0.0% |
| Employees | 2 | -77.8% |
| Net Income | -$0.97M | 48.8% |
| EBITDA | -$0.93M | 50.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.52M | 586.3% |
| Accounts Receivable | $0.04M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.84M | 951.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.01% | 4.7% |
| Return On Invested Capital | 216.52% | 60.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.86M | 53.7% |
| Operating Free Cash Flow | -$0.86M | 53.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.76 | -0.44 | -0.30 | -1.26 | -746.44% |
| Price to Tangible Book Value | 1.32 | -1.23 | -0.83 | -1.00 | 100.75% |
| Enterprise Value to EBITDA | -53.69 | -78.82 | -100.83 | -78.68 | 136.04% |
| Return on Equity | -51.5% | -33.2% | -24.3% | -18.7% | -15.72% |
| Total Debt | $0.14M | $0.84M | $0.84M | $0.84M | 423.34% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
